
Health advocates urge Carney to respect pledge for UN Global Fund fighting AIDS, TB
"While some of the other nations around the world are retreating right now from investing in global health, Canada can and should be stepping forward swiftly, to save lives," said Justin McAuley, a director with the Canadian branch of the ONE Campaign.
His group is among 24 Canadian civil society organizations that asked the government to allocate $1.37 billion over three years for the Global Fund to Fight AIDS, tuberculosis and malaria.
The fund is affiliated with the United Nations, and it supports developing countries in limiting and treating the three preventable illnesses, which in many regions are among the leading causes of death.
Canada is one of the world's top supporters of the fund, which makes up the largest chunk of Ottawa's global health spending. Canada has contributed nearly $5 billion to the Global Fund since 2002, and the fund estimates it has saved 65 million lives in that time.
Countries replenish the fund every three years, with their contributions usually rising over time as health-care systems build more capacity to treat and prevent these diseases.
In each cycle, civil society groups issue what they call a fair-share metric to reflect how much each wealthy country can reasonably pledge to help the fund reach its goals.
The office of Randeep Sarai, secretary of state for international development, referred questions about the $1.37 billion request to Global Affairs Canada.
"Canada looks forward to working together as part of the Global Fund partnership to secure a successful eighth replenishment of the fund this year," the department wrote in a statement. "Discussions regarding Canada's pledge are ongoing."
McAuley said he hopes Ottawa announces its pledge soon, to build momentum for other countries to follow suit.
"Canada has a unique role and legacy to play in the global health space," he said. "Our momentum will mean something on the world stage — if we come out early, and don't wait for the last minute."
Results Canada, another group asking Ottawa to meet the civil society target, noted the G7 summit that Canada hosted in Alberta "focused on trade, conflict and climate — but overlooked two of the most powerful tools for global stability: health and education."
That has put the legacy of the Global Fund "under threat," the group argued in an email campaign. "As countries cut international assistance, decades of hard-won gains hang in the balance."
UNAIDS reported on July 10 that HIV infections and deaths continue to drop, but sudden cuts by the United States and others "threaten to reverse years of progress in the response to HIV."
US Republicans recently reversed plans to cut PEPFAR, the world's largest HIV program, but Washington is still on track to slash its contribution to the Global Fund.
Countries normally make pledges at an organized conference, such as the last cycle when prime minister Justin Trudeau visited the United Nations in New York in 2022.
This year, there is no pledging conference, though McAuley expects leaders of large economies to make pledges before visiting South Africa for the G20 summit in November.
He said global health is already under pressure from armed conflicts, climate-related events and the ongoing recovery of health systems from cutbacks during the COVID-19 pandemic. Rich countries are cutting back on foreign aid as they increase military spending.
Prime Minister Mark Carney promised in last spring's election to not cut foreign aid spending or development financing, though this was before he launched a review of government spending and committed to large amounts of military-related spending.
McAuley said Carney ought to meet the metric outlined by civil society, or he'll be offside with his two last predecessors.
"Both Harper and Trudeau repeatedly stepped up and did Canada's fair share," he said. "Is Carney going to break that pattern now and step back?"
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
23 minutes ago
- Cision Canada
Rocket Science Health Secures U.S Patent for Precision Intranasal Drug Delivery Platform
Patent covers a method of targeted drug delivery to the brain and central nervous system via subregions of the intranasal cavity Builds on recent corporate milestones and sets the stage for future strategic partnerships Advances Rocket Science Health's progression towards broader clinical applications VICTORIA, BC, July 30, 2025 /CNW/ - Rocket Science Health Corp., a Canadian healthcare technology company focused on precision drug delivery for brain therapeutics and vaccines, today announced it has secured U.S. Patent No. 12,343,489 from the United States Patent and Trademark Office for its investigational precision intranasal drug delivery device. The patent covers a method of targeted delivery of therapeutic compositions to subregions of the intranasal cavity, including the olfactory, dispensed from a vantage point that is essential for maximizing on-target and avoiding off-target delivery of drugs. "Getting drugs to the brain is one of medicine's hardest problems and our proprietary technology is designed to address that challenge – not just for brain delivery, but also for vaccines and other treatments that need more targeted approaches. It's not rocket science, but a simple drug delivery device that has the potential to make sophisticated drugs work, while broadening access to live-saving treatments," said Sohier Hall, President of Rocket Science Health. "The granting of these key patents is an important milestone on our journey to scale and accelerate the delivery of next-generation brain and central nervous system treatments, with the goal of initiating human clinical trials with our device in the near future." The upper nasal cavity offers a unique access point to the brain and central nervous system that can optimize the brain's exposure to drug therapies, accelerate the onset of action, reduce drug doses, improve the accuracy of delivery, and potentially improve health outcomes for millions of patients. However, commercially available nasal spray devices can only deliver a fraction of their dose volume to the olfactory region due to the anatomical characteristics of the nasal cavity. At the same time, nearly all small and large molecule drug therapies approved by the FDA cannot enter the central nervous system when taken through other, traditional routes of administration. Initial peer-reviewed research and in-human imaging studies have validated Rocket Science Health's patented technology and demonstrated precise, repeatable drug deposition to subregions of the intranasal cavity. This technology is compatible with delicate drug formulations, including lipid nanoparticles (LNPs), biologics, peptides, and can handle a range of viscosities. The Company is evaluating licensing of its technology to developers where precision delivery is a potential factor for success in their pending clinical trial. The intellectual property applies to both next-generation therapies or reestablishing existing molecules with greater effect and patent ability. With strong intellectual property, validated in-human results, and industry-leading execution partners in place, Rocket Science is well-positioned to advance toward broader clinical applications in brain-targeted drug delivery. For more information on Rocket Science Health, visit About Rocket Science Health: Rocket Science Health, founded by Canadian business leader Kenneth Irving, develops precision drug delivery technologies focused on brain-targeted therapeutics and vaccines. Our needle-free intranasal device enables non-clinical self-administration for at-home care, emergency rescue, and mass immunization. Its fluidics are specifically engineered for today's delicate biologics and dose-dependent drugs. As a team, we are driven to create innovations that expand access to care—especially for under-resourced communities and for individuals who face physical, cognitive, or challenging care environments where thoughtful design can improve health outcomes.


Cision Canada
2 hours ago
- Cision Canada
Specsavers to Open 111 New Optical Locations in Loblaw Grocery Stores Across Canada Français
Specsavers locations will open in select Loblaw grocery stores across Canada – including in Loblaws, Real Canadian Superstore and Zehrs stores – while maintaining seamless continuity for customers and patients, and significantly expanding access to advanced eye care services including Optical Coherence Tomography (OCT) technology. The expansion also represents Specsavers' entry into five new provinces — New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, and Saskatchewan — and one new territory, Yukon, while strengthening its presence in British Columbia, Alberta, Manitoba, and Ontario. "This expansion represents a pivotal moment for eye care accessibility in Canada," said Bill Moir, Managing Director of Specsavers Canada. "By opening 111 new locations within trusted Loblaw locations, we're fundamentally improving how Canadians access the eye care they deserve. Our mission has always been to change lives through better sight; we believe expert eye care and quality eyewear should be affordable for all. We are now able to expand that mission across the country, ensuring that more families can access comprehensive optical services in the communities where they already shop." New Specsavers locations will operate within existing Loblaws stores, providing customers and patients with convenient access to comprehensive eye examinations, prescription eyewear, contact lenses, and specialized eye care services. All locations will be staffed by qualified independent optometrists and opticians. "Theodore & Pringle was born from the belief that eye care should be convenient and affordable for everyone," said Irene Doody, Head of Optical, Loblaw Companies Limited. "Specsavers' reputation for accessible eye care aligns perfectly with our purpose - to help Canadians live life well. Specsavers will provide a seamless transition for our optical customers while introducing them to a trusted global leader in eye care." The first wave of new Specsavers locations within Loblaw stores is scheduled to open in September 2025, with additional locations following throughout the remainder of the year. About Specsavers Specsavers is an optometrist-owned business that entered the Canadian market in late 2021. Since then, over 150 locations have opened across the country, in B.C., Alberta, Ontario, and Manitoba. As part of Specsavers' commitment to accessible eyecare, Specsavers equips every location with optical coherence tomography (OCT) technology, which helps optometrists to detect sight-threatening conditions, such as age-related macular degeneration, glaucoma and diabetic eye disease, in their earliest stages. Founded in the UK over 40 years ago by optometrist husband-and-wife team, Doug and Mary Perkins, there are now more than 2,700 Specsavers healthcare businesses globally, serving over 44 million patients and customers. Specsavers is driven by its purpose of "changing lives through better sight" and aims to transform the way Canadians experience eyecare by offering exceptional service, advanced clinical equipment and quality eyewear. For more information, please visit About Loblaw Companies Limited Loblaw is Canada's food and pharmacy leader, and the nation's largest retailer. Loblaw provides Canadians with grocery, pharmacy, and healthcare services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada's largest private sector employers. Loblaw's purpose – Live Life Well ® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company's stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart ® and Pharmaprix ® locations and in close to 500 grocery stores; PC Financial ® services; Joe Fresh ® fashion and family apparel; and four of Canada's top-consumer brands in Life Brand ®, Farmer's Market™, no name ® and President's Choice ®. For more information, visit Loblaw's website at and Loblaw's issuer profile at


Calgary Herald
12 hours ago
- Calgary Herald
Chronic wound patients get new hope from Calgary health tech company
Article content It could also change lives. Chronic wounds have been a scourge of health care for millennia; signs of pressure sores have been found in Egyptian mummies, Florence Nightingale reportedly said that a bed sore was 'generally not the fault of the disease, but of nursing.' Still, chronic wounds continue to keep millions of patients in hospital, in treatment, in discomfort and at risk. Article content Doing something to change the trajectory of chronic wounds became a mission of Julian Mulia, a chemical engineer originally from Mexico, who was inspired to look for solutions after losing both parents to chronic conditions, including managing wounds. He is chief operating officer of Calgary-based NanoTess. Co-founder Megan Leslie is CEO. Article content Article content The company describes its salve as a catalyst that uses the body's natural healing reactions to promote faster healing and reduce inflammation. Article content Article content 'Essentially, when a body is trying to heal a wound, it's like pushing a rock up a mountain. And a lot of us don't of the energy or resources to help make that (healing) reaction go to completion, which is where you get into chronic wound territory and your body just can't heal itself,' said Larissa Lalonde, strategy lead at the company. Article content What the salve does, Lalonde said, is lower the energy it takes to heal the wound 'so that more of those healing reactions can take place faster and better.' Article content During a provincial commercialization project funded by the CAN Health Network and conducted by Alberta Health Services and the University of Calgary, integrating the product into treatment improved wound healing in chronic wounds by 57.6 per cent. Those were wounds that had not healed for an average of more than one and a half years. Article content Bruyère, which has the largest specialty wound treatment unit as well as the only complex care facility in eastern Ontario, is also part of the CAN Health Network, a federally funded agency that supports Canadian health-care innovation. Based on validation by the Alberta Health Service, it tried out the product earlier this year, and it now plans to expand its use, DeZeeuw said. Article content Article content 'My goal is to get it throughout Bruyère Health,' she said. 'It has the potential to really help a lot of people.' Other nearby hospitals and long-term care homes are also looking at it, she said, and it is being used across Canada. Article content 'To my knowledge, there has not been a really significant breakthrough that has kind of flipped wound care on its head — at least since I have been in medical training,' DeZeeuw said. 'I am hopeful that this ends up being really helpful for at least a significant proportion of patients.' Article content That includes many people in hospital beds and long-term care homes across the country suffering from chronic bed sores, diabetic foot ulcers and complex surgical incisions. In some cases, chronic wounds keep them bedridden or away from their homes and families. Article content When a body is trying to heal a wound, it's like pushing a rock up a mountain. And a lot of us don't of the energy or resources to help make that (healing) reaction go to completion. Larissa Lalonde 'Often you suffer alone if you are dealing with a wound,' said Lalonde of NanoTess. 'It is not something that people typically talk openly about. But, when you do start to talk about it with friends or family, you realize how widespread this issue is.'